Multicenter prospective observational study of the comparative efficacy and safety of vancomycin versus teicoplanin in patients with health care-Associated methicillin-resistant staphylococcus aureus bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 317-324

  Yoon, Young Kyung ^a   Park, Dae Won ^a   Sohn, Jang Wook ^a   Kim, Hyo Youl ^b   Kim, Yeon Sook ^c   Lee, Chang Seop ^d   Lee, Mi Suk ^e   Ryu, Seong Yeol ^f   Jang, Hee Chang ^g   Choi, Young Ju ^h   Kang, Cheol In ⁱ   Choi, Hee Jung ^j   Lee, Seung Soon ^k   Kim, Shin Woo ⁱ   Kim, Sang Il ^l   Kim, Eu Suk ^m   Kim, Jeong Yeon ⁿ   Yang, Kyung Sook ^o   Peck, Kyong Ran ^p   Kim, Min Ja ^a  

^a Korea University   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

^c Chungnam National University College of Medicine   (South Korea)

^d Chonbuk National University Medical School   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

^f Keimyung University   (South Korea)

^g Chonnam National University Medical School   (South Korea)

^h National Cancer Center   (South Korea)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j Ewha Womans University School of Medicine   (South Korea)

^k Hallym University   (South Korea)

^l Kyungpook National University Hospital   (South Korea)

^m The Catholic University of Korea   (South Korea)

ⁿ Seoul National University Bundang Hospital   (South Korea)

^o Samyook Medical Center   (South Korea)

^p Korea University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EPSILOMETER TEST; FEMALE; FEVER; HUMAN; KIDNEY INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; TEICOPLANIN; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84891521080     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00520-13     Document Type: Article

References (38)

1. Primo MG, Guilarde AO, Martelli CM, Batista LJ, Turchi MD. 2012. Healthcare-associated Staphylococcus aureus bloodstream infection: length of stay, attributable mortality, and additional direct costs. Braz. J. Infect. Dis. 16:503-509. http://dx.doi.org/10.1016/j.bjid.2012.10.001.
2. Park SY, Son JS, Oh IH, Choi JM, Lee MS. 2011. Clinical impact of methicillin-resistant Staphylococcus aureus bacteremia based on propensity scores. Infection 39:141-147. http://dx.doi.org/10.1007/s15010-011-0100-1.
3. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC, Jr. 2004. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. 38:1700-1705. http://dx.doi.org/10.1086/ 421092.
4. Jacob JT, Diazgranados CA. 2013. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillinresistant Staphylococcus aureus infections: A meta-analysis. Int. J. Infect. Dis. 17:e93- e100. http://dx.doi.org/10.1016/j.ijid.2012.08.005.
5. van Hal SJ, Lodise TP, Paterson DL. 2012. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin. Infect. Dis. 54:755-771. http://dx.doi.org/10.1093/cid/cir935.
6. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. 2009. Vancomycin therapeutic guidelines: A summary of consensus recommendations from the infectiousdiseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327. http://dx.doi.org/10.1086/ 600877.
7. Brown J, Brown K, Forrest A. 2012. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob. Agents Chemother. 56:634-638. http://dx.doi.org/10.1128/AAC.05609-11.
8. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. 2009. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis. 49:507-514. http://dx.doi.org/10.1086/600884.
9. Verbist L, Tjandramaga B, Hendrickx B, Van Hecken A, Van Melle P, Verbesselt R, Verhaegen J, De Schepper PJ. 1984. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob. Agents Chemother. 26:881-886. http://dx.doi.org/10.1128/AAC.26.6.881.
10. Svetitsky S, Leibovici L, Paul M. 2009. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob. Agents Chemother. 53:4069-4079. http://dx.doi.org/10.1128/AAC.00341- 09.
11. Williams AH, Gruneberg RN. 1988. Teicoplanin revisited. J. Antimicrob. Chemother. 22:397-401. http://dx.doi.org/10.1093/jac/22.4.397.
12. Pedrera MI, Barriga C, Rodriguez AB. 1995. Intracellular activity of both teicoplanin and vancomycin against Staphylococcus aureus in human neutrophils. Comp. Immunol. Microbiol. Infect. Dis. 18:123-128. http://dx.doi.org/10.1016/ 0147-9571(95)98853-A.
13. Lin SH, Lai CC, Tan CK, Liao WH, Hsueh PR. 2011. Comparative efficacy of vancomycin and teicoplanin in the treatment of hospitalised elderly patients with persistent meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia. Int. J. Antimicrob. Agents 37:179-181. http://dx.doi.org/10.1016/j.ijantimicag. 2010.10.018.
14. Chang HJ, Hsu PC, Yang CC, Siu LK, Kuo AJ, Chia JH, Wu TL, HuangCT, Lee MH. 2012. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: A hospital-based retrospective study. J. Antimicrob. Chemother. 67:736-741. http://dx.doi.org/10.1093/jac/dkr531.
15. Gilbert DN, Moellering RC, Jr, Eliopoulos GM (ed). 2010. The Sanford guide to antimicrobial therapy 2010, 40th ed. Antimicrobial Therapy, Sperryville, VA.
16. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002.
17. Longo DL, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. 2012. Harrison's principles of internal medicine, 18th ed. McGraw-Hill, New York, NY.
18. O'Brien FG, Lim TT, Chong FN, Coombs GW, Enright MC, Robinson DA, Monk A, Said-Salim B, Kreiswirth BN, Grubb WB. 2004. Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J. Clin. Microbiol. 42:3185-3190. http://dx.doi.org/10.1128/JCM.42.7.3185-3190.2004.
19. David MZ, Glikman D, Crawford SE, Peng J, King KJ, Hostetler MA, Boyle-Vavra S, Daum RS. 2008. What is community-associated methicillin- resistant Staphylococcus aureus? J. Infect. Dis. 197:1235-1243. http://dx.doi.org/10.1086/533502.
20. Charlson M, Szatrowski TP, Peterson J, Gold J. 1994. Validation of a combined comorbidity index. J. Clin. Epidemiol. 47:1245-1251. http://dx.doi.org/10.1016/0895-4356(94)90129-5.
21. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. 1985. APACHE II: A severity of disease classification system. Crit. Care Med. 13:818-829. http://dx.doi.org/10.1097/00003246-198510000-00009.
22. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. 1991. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann. Intern. Med. 115:585-590. http://dx.doi.org/10.7326/0003-4819-115-8-585.
23. Lee K, Kim MN, Kim JS, Hong HL, Kang JO, Shin JH, Park YJ, Yong D, Jeong SH, Chong Y. 2011. Further increases in carbapenem-, amikacin-,and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med. J. 52:793-802. http://dx.doi.org/10.3349/ ymj.2011.52.5.793.
24. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. 2003. Comparison of mortality associated with methi- cillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis. 36:53-59. http://dx.doi.org/10.1086/345476.
25. Moore CL, Lu M, Cheema F, Osaki-Kiyan P, Perri MB, Donabedian S, Haque NZ, Zervos MJ. 2011. Prediction of failure in vancomycin-treated methicillin-resistant Staphylococcus aureus bloodstream infection: A clinically useful risk stratification tool. Antimicrob. Agents Chemother. 55: 4581-4588. http://dx.doi.org/10.1128/AAC.00115-11.
26. Hall RG, II, Giuliano CA, Haase KK, Hazlewood KA, Frei CR, Forcade NA, Brouse SD, Bell T, Bedimo RJ, Alvarez CA. 2012. Empiric guideline- recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: A retrospective cohort study. BMC Infect. Dis. 12:104. http://dx.doi.org/10.1186/1471-2334-12-104.
27. Lin SH, Liao WH, Lai CC, Liao CH, Tan CK, Wang CY, Huang YT, Hsueh PR. 2010. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan. J. Antimicrob. Chemother. 65:1792-1798. http://dx.doi.org/ 10.1093/jac/dkq188.
28. Liao CH, Chen SY, Huang YT, Hsueh PR. 2008. Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan. Int. J. Antimicrob. Agents 32:326-332. http://dx.doi.org/10.1016/j.ijantimicag.2008.04.011.
29. Wang JL, Wang JT, Sheng WH, Chen YC, Chang SC. 2010. Nosocomialmethicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan:mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect. Dis. 10:159. http://dx.doi.org/10.1186/ 1471-2334-10-159.
30. Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. 2010. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst. Rev. 2010:CD007022. http://dx.doi.org/10.1002/14651858.CD007022. pub2.
31. Wood MJ. 1996. The comparative efficacy and safety of teicoplanin and vancomycin. J. Antimicrob. Chemother. 37:209-222. http://dx.doi.org/10.1093/jac/ 37.2.209.
32. Huang JH, Hsu RB. 2008. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study. Scand. J. Infect. Dis. 40:462-467. http://dx.doi.org/10. 1080/00365540701837126.
33. Liu C-Y, Lee W-S, Fung C-P, Cheng N-C, Liu C-L, Yang S-P, Chen S-L. 1996. Comparative study of teicoplanin vs vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin. Drug Invest. 12:80-87. http://dx.doi.org/10.2165/00044011-199612020-00003.
34. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, M JR, Talan DA, ChambersHF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
35. Park HJ, Kim SH, Kim MJ, Lee YM, Park SY, Moon SM, Park KH, Chong YP, Lee SO, Choi SH, Woo JH, Kim YS. 2012. Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J. Infect. 65:505-512. http://dx.doi.org/10.1016/j.jinf.2012.08.007.
36. Hsiao SH, Chou CH, Lin WL, Lee EJ, Liao LH, Chang HJ, Yeh PY, Lin CY, Wu TJ. 2012. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy. J. Clin. Pharm. Ther. 37:296-300. http://dx.doi.org/10. 1111/j.1365-2710.2011.01291.x.
37. Hung YP, Lee NY, Chang CM, Lee HC, Wu CJ, Chen PL, Lee CC, Chung CH, Ko WC. 2009. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: A retrospective chart review. Clin. Ther. 31:1977-1986. http://dx.doi.org/10.1016/j.clinthera.2009.09.010.
38. DeRyke CA, Alexander DP. 2009. Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentration- time curve/minimum inhibitory concentration. Hosp. Pharm. 44: 751-765. http://dx.doi.org/10.1310/hpj4409-751.